Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia.
作者信息
Crickx Etienne, Moulis Guillaume, Ebbo Mikael, Terriou Louis, Briantais Antoine, Languille Laetitia, Limal Nicolas, Guillet Stéphanie, Michel Marc, Mahevas Matthieu, Godeau Bertrand
机构信息
Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France.
Department of Internal Medicine, Toulouse University Hospital (CHU de Toulouse), Toulouse, France.
出版信息
Br J Haematol. 2021 Dec;195(5):703-705. doi: 10.1111/bjh.17813. Epub 2021 Aug 31.
Abstract
摘要
相似文献
1
Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia.
Br J Haematol. 2021 Dec;195(5):703-705. doi: 10.1111/bjh.17813. Epub 2021 Aug 31.
2
Severe immune thrombocytopenia after COVID-19 vaccination: Report of four cases and review of the literature.
Blood Cells Mol Dis. 2021 Dec;92:102615. doi: 10.1016/j.bcmd.2021.102615. Epub 2021 Oct 7.
3
Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry.
Viruses. 2022 Jan 18;14(2):178. doi: 10.3390/v14020178.
4
Immune Thrombocytopenia (ITP): Relapse Versus de novo After COVID-19 Vaccination.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296211073920. doi: 10.1177/10760296211073920.
5
Platelet trends after Covid-19 vaccination in patients with chronic or persistent immune thrombocytopenia.
Am J Hematol. 2021 Dec 1;96(12):E472-E474. doi: 10.1002/ajh.26366. Epub 2021 Oct 19.
6
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
Lancet. 2022 Feb 12;399(10325):625-626. doi: 10.1016/S0140-6736(22)00090-3. Epub 2022 Jan 18.
7
Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
Clin Microbiol Infect. 2022 Jun;28(6):885.e1-885.e5. doi: 10.1016/j.cmi.2022.02.010. Epub 2022 Feb 16.
8
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
BMC Cancer. 2021 Dec 27;21(1):1354. doi: 10.1186/s12885-021-09097-5.
9
Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.
J Infect Dis. 2022 Mar 2;225(5):777-784. doi: 10.1093/infdis/jiab579.
10
Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine.
Am J Hematol. 2021 May 1;96(5):E133-E134. doi: 10.1002/ajh.26106. Epub 2021 Feb 11.
引用本文的文献
1
Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis.
Eur J Med Res. 2024 Jan 17;29(1):55. doi: 10.1186/s40001-024-01639-4.
2
Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective.
Ann Hematol. 2023 Jul;102(7):1645-1656. doi: 10.1007/s00277-023-05266-7. Epub 2023 May 12.
3
Proceedings of the immune thrombocytopenia summit: new concepts in mechanisms, diagnosis, and management.
Res Pract Thromb Haemost. 2023 Feb 27;7(2):100097. doi: 10.1016/j.rpth.2023.100097. eCollection 2023 Feb.
4
COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panic.
Res Pract Thromb Haemost. 2023 Jan;7(1):100039. doi: 10.1016/j.rpth.2023.100039. Epub 2023 Feb 15.
5
Older Adults and Immune Thrombocytopenia: Considerations for the Clinician.
Clin Interv Aging. 2023 Jan 26;18:115-130. doi: 10.2147/CIA.S369574. eCollection 2023.
6
Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway.
Eur Heart J Open. 2022 May 16;2(3):oeac036. doi: 10.1093/ehjopen/oeac036. eCollection 2022 May.
7
SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia.
Pediatr Blood Cancer. 2022 Jul;69(7):e29760. doi: 10.1002/pbc.29760. Epub 2022 May 13.
8
De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring.
Blood. 2022 Apr 21;139(16):2561-2565. doi: 10.1182/blood.2022015470.
9
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination.
Int J Mol Sci. 2022 Mar 19;23(6):3338. doi: 10.3390/ijms23063338.
10
Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia.
J Thromb Haemost. 2022 Jun;20(6):1476-1484. doi: 10.1111/jth.15704. Epub 2022 Apr 5.
本文引用的文献
1
Exacerbation of immune thrombocytopenia following COVID-19 vaccination.
Br J Haematol. 2021 Nov;195(3):365-370. doi: 10.1111/bjh.17645. Epub 2021 Jun 24.
2
Immune thrombocytopenia during the COVID-19 pandemic.
Br J Haematol. 2021 Jun;193(6):1093-1095. doi: 10.1111/bjh.17457. Epub 2021 Apr 14.
3
Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.
Am J Hematol. 2021 May 1;96(5):534-537. doi: 10.1002/ajh.26132. Epub 2021 Mar 9.
4
Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series.
Br J Haematol. 2020 Aug;190(4):e224-e229. doi: 10.1111/bjh.17024. Epub 2020 Aug 4.
5
Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19.
Br J Haematol. 2020 Sep;190(5):e276-e279. doi: 10.1111/bjh.16950. Epub 2020 Aug 31.
6
COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature.
J Med Virol. 2021 Jan;93(1):43-45. doi: 10.1002/jmv.26138. Epub 2020 Jun 29.
7
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
8
American Society of Hematology 2019 guidelines for immune thrombocytopenia.
Blood Adv. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966.
Zotero 插件